# Radar

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/radar
Canonical HTML page: https://getbiobrief.com/entity/radar

## Timeline

- **2026-06-30**: Q2 2026 closes with $804M total VC — San Diego records third-lowest quarterly venture capital investment of the decade across 62 deals.
- **2026-06**: Radar secures $171M round — AI retail intelligence platform closes San Diego's largest Q2 deal, with sensors deployed in American Eagle and Old Navy stores.
- **2026-04**: Rakuten Medical raises $111M — San Diego biotech secures funding for Phase 3 head & neck cancer trial of Alluminox platform.

## Recent coverage (1 stories)

### SD Biotechs Top SF Returns, Yet $804M Q2 Funding Imperils Drug Pipeline
2026-08-03 07:50:06 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

San Diego biotechs are delivering better returns than Bay Area rivals but raised only $804M in Q2 2026, a decade low. The capital shortage threatens clinical trials like Rakuten Medical’s Phase 3 Alluminox study. Without a reversal, the region’s proven therapy engine could stall.
Full story: https://getbiobrief.com/story/sd-biotechs-804m-funding-drought

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.